David Blake

<i>In vitro</i> and <i>in vivo</i> antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)

Steven J. McClue, David Blake, Rosemary G. Clarke et al. · International Journal of Cancer · 2002 · 363 citations · Full text

Medicine, Oncology, Pharmacology +15

Regulation of human γ-glutamylcysteine synthetase: co-ordinate induction of the catalytic and regulatory subunits in HepG2 cells

Claire Galloway, David Blake, A. Graeme SHEPHERD et al. · Biochemical Journal · 1997 · 106 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15

Discovery of<i>N</i>-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors

Shudong Wang, Carol Midgley, Frédéric Scaërou et al. · Journal of Medicinal Chemistry · 2010 · 101 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Discovery and Characterization of 2-Anilino-4- (Thiazol-5-yl)Pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents

Shudong Wang, Gary Griffiths, Carol Midgley et al. · Chemistry & Biology · 2010 · 101 citations · Full text

Medicine, Medicinal Chemistry, Oncology +14

A Quantitative Study of the in Vitro Binding of the C-Terminal Domain of p21 to PCNA:  Affinity, Stoichiometry, and Thermodynamics

Daniella Zheleva, Nikolai Zhelev, Peter M. Fischer et al. · Biochemistry · 2000 · 87 citations

Life Sciences, Biochemistry, Molecular Biology +17